Concise Prescribing Info
Management of schizophrenia & treatment of moderate to severe mania associated w/ bipolar disorder.
Dosage/Direction for Use
Adult Schizophrenia & prevention of recurrence in bipolar disorder Starting dose: 10 mg/day. Subsequently adjusted w/in the range of 5-20 mg/day. Manic episode Starting dose: 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Subsequently adjusted w/in the range of 5-20 mg/day.
May be taken with or without food: Place in the mouth & allow to dissolve completely then, swallow w/ saliva. Alternatively, disperse in a full glass of water or other beverages (orange juice/apple juice/milk/coffee) immediately prior administration.
Hypersensitivity. Known risk of narrow-angle glaucoma.
Special Precautions
Not for treatment of dementia-related psychosis &/or behavioural disturbances; dopamine agonist associated psychosis in patients w/ Parkinson's disease. Neuroleptic malignant syndrome. Hyperglycemia &/or development or exacerbation of diabetes. Lipid alterations. Prostatic hypertrophy or paralytic ileus. Renal & hepatic impairment; patients receiving potentially hepatotoxic drugs. Discontinue use if hepatitis occurs. Patients w/ low leukocyte &/or neutrophil counts, receiving drugs known to cause neutropenia, history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy, hypereosinophilic conditions & myeloproliferative disease. Avoid abrupt w/drawal. Congenital long QT syndrome, CHF, heart hypertrophy, hypokalemia or hypomagnesemia & concomitant use w/ drugs known to increase QTc interval. Venous thromboembolism. Concomitant use w/ other centrally acting drugs & alcohol. Seizures. Tardive dyskinesia. Postural hypotension; periodically monitor BP especially in the elderly ≥65 yr. Sudden cardiac death. Phenylketonuria. Pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Somnolence, wt gain, eosinophilia, elevated prolactin, cholesterol, glucose & triglyceride levels, glucosuria, increased appetite, dizziness, akathisia, parkinsonism, dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases, rash, asthenia, fatigue & edema.
Drug Interactions
Reduced conc w/ carbamazepine & smoking. Metabolism inhibited by fluvoxamine & ciprofloxacin. Reduced bioavailability w/ activated charcoal. May antagonize the effects of direct & indirect dopamine agonists. Alcohol, CNS depressants, antiparkinsonian drugs. Drugs known to increase QTc interval.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Lupilan orodispersible tab 10 mg
30's (P141/orodispersible tab)
Lupilan orodispersible tab 5 mg
30's (P84/orodispersible tab)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in